Predictors of vision-related quality of life in patients with macular oedema receiving intra-vitreal anti-VEGF treatment.

Abstract

PurposeTo determine which demographic and clinical characteristics are predictive of vision‐related quality of life (VrQoL) and quality of life (QoL) in patients with macular oedema receiving intravitreal anti‐vascular endothelial growth factor (VEGF) treatment.MethodsVision‐related quality of life (VrQoL) and quality of life (QoL) were measured in 712 patients with retinal exudative disease receiving anti‐VEGF treatment at baseline, 6 and 12 months. VrQoL was measured using an item‐response theory based 47‐question item bank (EyeQ), whereas QoL was measured using the EuroQol Five Dimensions (EQ‐5D) questionnaire. The EQ‐5D score was dichotomized into a perfect score of 1 and a suboptimal score of <1. Demographic and clinical patient characteristics were considered as possible predictors of (Vr)QoL. Prediction models for (Vr)QoL were created with linear mixed models and generalised estimating equations, using a forward selection procedure.ResultsA worse VrQoL was predicted by poorer LogMAR visual acuity of the better eye, female sex, single civil status, older age, longer length of anti‐VEGF treatment at baseline and the presence of non‐ocular and ocular comorbidities. Suboptimal EQ‐5D scores were predicted by poorer LogMAR visual acuity of the better eye, female sex, single civil status, older age, the presence of non‐ocular comorbidities and a lower educational background.ConclusionsAlong with visual acuity of the better eye, which is the main factor used in clinical decision making, other patient characteristics should also be considered for the risk assessment of (Vr)QoL, such as sex, age, civil status, comorbidities and length of anti‐VEGF treatment.